Navigation Links
AMRESCO Invests in New Powder Manufacturing Facility to Support Growth in Life Science Business

Cleveland, Ohio (PRWEB) June 25, 2013

AMRESCO, LLC, a VWR company and a Life Science leader in the supply and contract manufacturing of high purity biochemicals, reagents and research products, announced that it has invested in a new powder manufacturing facility to support growing global business to Diagnostic, Molecular Biology and Biopharmaceutical companies. AMRESCO’s investment is part of its ongoing strategy to help increase its customers’ operational efficiencies and profitability. Its breadth of services and manufacturing capabilities offers a strong value platform and strengthens its mission to support customers and their products.

AMRESCO’s new facility increases its powder manufacturing capacity by 150%, expanding capabilities for particle size reduction, homogenous powder blending, precision powder dosing for pouching, and tablet production. This expanded and enhanced production helps to support growing product lines such as buffer blends and dehydrated media blends.

Over 35% of AMRESCO’s customers require specific formulation needs. The additional powder manufacturing capabilities and capacity allow AMRESCO to manufacture, dose and package a wider variety of powder products with varying volumes, as well as offer customers the sensitivity and most importantly, the throughput that their product requires.

Jim Taliak, VP of Global Sales at AMRESCO states, “Our customers are challenged with speed to market, operational constraints, and lack of capital or expertise. They are focusing on activities and efforts that don’t always align with their best strategic interest. Together, we look at where they need to be, then employ our skill and capabilities to assure their success.”

For nearly four decades, AMRESCO has been serving life sciences research and commercial production customers worldwide, bringing them high purity biochemicals, custom manufacturing solutions, innovative research products and strategic services including Product Design, Transfer and Engineering. AMRESCO products and services support the growing In Vitro Diagnostic, Molecular Diagnostic, Life Science Tool Providers and Biopharm market segments.

For further information, contact: Deborah Neilly, Marketing and Communications
V: 440.914.3311 E: dneilly(at)amresco-inc(dot)com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. AMRESCO’s New Fluorescent DNA Quantitation Kit Uses a Highly Specific DNA-binding Dye that Allows Accurate Quantitation Even in Crude Extracts
2. AMRESCO’s New VisiGlo™ Prime and VisiGlo™ Select HRP Chemiluminescent Substrate Kits Offer Long-lasting, High Sensitivity Detection
3. AMRESCO Offers New Prism Protein Marker With Vibrant Colors For Easy Band Identification
4. DuPont, American Farm Bureau Foundation Invests $250,000 in My American Farm Web Education Program
5. UPMC Invests in Intelligent Infrastructure with IBM to Support Vision of Personalized Medicine
6. JumpStart Invests $250,000 in Milo Biotechnology
7. AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
8. SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities
9. TM&S Opens Office Dedicated to Powder Metal, Metal Injection Molding and Liquid Metal
10. Rigaku Publishes New Application for Cement Analysis by the Pressed Powder Method on the ZSX Primus III+ According to ASTM C114-11
11. Rigaku Publishes New Application Note: Cement Raw Meal Analysis by Pressed Powder Method on the ZSX Primus III+
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):